At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 330 enrolled
Drug / intervention
Azithromycin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Parallel Group, Double Blinded, 1:1, Randomized Controlled Phase III Trial of Co-trimoxazole Versus Azithromycin for the Treatment of Undifferentiated Fever In Nepal
Oxford University Clinical Research Unit, Vietnam·interventional·Posted May 16, 2016·Updated Dec 6, 2023
In Brief
A Phase 3 clinical trial evaluating Azithromycin and Co-trimoxazole for Undifferentiated Febrile Illness. Completed, enrolled 330 participants across 2 sites.
Detailed Summary
The purpose of the study is to determine whether azithromycin or cotrimoxazole is the best empirical treatment for undifferentiated febrile illness in Nepal
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUndifferentiated Febrile Illness
CountriesNepal
CollaboratorsUniversity of Oxford, Wellcome Trust
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartMay 2016
Primary CompletionAug 2019
TodayJul 2026
First PostedMay 16, 2016
Enrollment StartMay 23, 2016
Primary CompletionAug 4, 2019
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 10.1 years ago
Interventions
Azithromycindrug
Co-trimoxazoledrug